Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2024
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
27 authors.
Ana M AparicioDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-0900-0923
Rebecca S S TidwellDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3041-8582
Shalini S YadavDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8266-5548
Jiun-Sheng ChenDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0708-6498
Miao ZhangDepartment of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4912-2570
Jingjing LiuDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0009-3197-2463
Shuai GuoDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0004-2988-5663
Patrick G PiliéDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8759-0020
Yao YuDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2727-1746
Xingzhi SongDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9436-2728
Haswanth VundavilliDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-3283-7732
Sonali JindalDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-3911-6815
Keyi ZhuDepartment of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0002-5225-2333
Paul V ViscuseDivision of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-0834-8688
Justin M LebenthalDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0003-0248-9583
Andrew W HahnDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4153-205X
Rama SoundararajanDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-6976-3784
Paul G CornDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4106-6335
Amado Zurita-SaavedraDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-3805-7307
Sumit K SubudhiDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5208-7732
Jianhua ZhangDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5412-9860
Wenyi WangDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-0617-9438
Chad HuffDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1100-9364
Patricia TroncosoDepartment of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-8241-1430
James P AllisonDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8980-5697
Padmanee SharmaDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4658-055X
Christopher J LogothetisDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6365-1711
Funding
Targeting Tumor Microenvironment-Induced Therapy Resistance in Prostate Cancer Bone MetastasisP50CA140388 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THOMPSON, TIMOTHY CHARLES · 2009 to 2022
$23.4M
Statistical methods for genomic analysis of heterogeneous tumorsR01CA268380 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Wenyi Wang · 2022 to 2026
$2.4M
Bristol Myers Squibb Foundation (BMSF) CA184-460Conquer Cancer Foundation (CCF) FP00011981MD Anderson Prostate Cancer ProgramNational Institutes of Health (NIH) P30 CA1016672National Institutes of Health (NIH) P50 CA 140388NCI NIH HHS P50 CA140388NCI NIH HHS R01 CA268380UT MD Anderson Cancer Center Prostate Cancer Moonshot
6 · The paper itself
Abstract
purposeTo determine the efficacy and safety of risk-adapted combinations of androgen signaling inhibitors and inform disease classifiers for metastatic castration-resistant prostate cancers. PATIENTS AND
methodsIn a modular, randomized phase II trial, 192 men were treated with 8 weeks of abiraterone acetate, prednisone, and apalutamide (AAPA; module 1) and then allocated to modules 2 or 3 based on satisfactory (≥50% PSA decline from baseline and <5 circulating tumor cell/7.5 mL) versus unsatisfactory status. Men in the former were randomly assigned to continue AAPA alone (module 2A) or with ipilimumab (module 2B). Men in the latter group had carboplatin + cabazitaxel added to AAPA (module 3). Optional baseline biopsies were subjected to correlative studies.
resultsMedian overall survival (from allocation) was 46.4 [95% confidence interval (CI), 39.2-68.2], 41.4 (95% CI, 33.3-49.9), and 18.7 (95% CI, 14.3-26.3) months in modules 2A (n = 64), 2B (n = 64), and 3 (n = 59), respectively. Toxicities were within expectations. Of 192 eligible patients, 154 (80.2%) underwent pretreatment metastatic biopsies. The aggressive-variant prostate cancer molecular profile (defects in ≥2 of p53, RB1, and PTEN) was associated with unsatisfactory status. Exploratory analyses suggested that secreted phosphoprotein 1-positive and insulin-like growth factor-binding protein 2-positive macrophages, druggable myeloid cell markers, and germline pathogenic mutations were enriched in the unsatisfactory group.
conclusionsAdding ipilimumab to AAPA did not improve outcomes in men with androgen-responsive metastatic castration-resistant prostate cancer. Despite the addition of carboplatin + cabazitaxel, men in the unsatisfactory group had shortened survivals. Adaptive designs can enrich for biologically and clinically relevant disease subgroups to contribute to the development of marker-informed, risk-adapted therapy strategies in men with prostate cancer.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. · full record | OpenQuestion